Table 1 The baseline characteristics of the study included in this study.
Author and year | Country or Region | Race | Cancer | Sample size | Males (%) | TNM stage | Kinase inhibitor | Criteria | Study design | Definition of response | Definition of non-response | Clinical outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ng 2012[1] | Singapore, Malaysia | Asian | Bcr-Abl1 positive CML | 138 | 58.70% | — | Imatinib | ELN | Retrospective | Optimal response | Suboptimal response or failure | Sensitive, resistant |
Ng 2012[2] | Japan | Asian | Bcr-Abl1 positive CML | 65 | 56.90% | — | Imatinib | ELN | Retrospective | Optimal response | Suboptimal response or failure | Sensitive, resistant |
Ng 2012[3] | Singapore, Japan | Asian | Mutant EGFR-NSCLC | 141 | 33.30% | III-IV, relapse | Gefitinib, erlotinib | — | Retrospective | — | — | PFS |
Katagiri 2013 | Japan | Asian | Bcr-Abl1 positive CML | 37 | — | — | Imatinib | ELN | Retrospective | Sustained CMR for >24 months | Fluctuating CMR for >24 months | Sustained or fluctuating CMR for >24 months |
Lee 2013 | Korea | Asian | Mutant EGFR-NSCLC | 193 | 37.10% | IIIB-IV, relapse | Gefitinib, erlotinib | RESCIST 1.1 | Retrospective | CR/PR | SD/PD | RR, DCR, PFS |
Shao 2013 | Taiwan | Asian | HCC | 89 | 89.90% | II-IV | Sorafenib | RESCIST 1.1 | Retrospective | CR/PR | SD/PD | RR, DCR, PFS, OS, |
Shinohara 2013 | Japan | Asian | Bcr-Abl1 positive CML | 144 | 65.80% | — | Imatinib | ELN | Prospective | CMR | Non-CMR | CMR, non-CMR |
Zheng 2013 | China | Asian | Mutant EGFR-NSCLC | 123 | 49.60% | IIIB-IV | Gefitinib, erlotinib | RESCIST 1.1, CTC3.0 | Retrospective | CR/PR | SD/PD | RR, DCR, PFS, adverse events |
Chen 2014 | China | Asian | Bcr-Abl1 positive CML | 220 | 50.90% | — | Imatinib | ELN | Retrospective | Optimal response | Suboptimal response or failure | Sensitive, resistant |
Isobe 2014 | Japan | Asian | Mutant EGFR-NSCLC | 70 | 27.10% | IV, relapse | Gefitinib, erlotinib | RESCIST 1.1, CTC3.0 | Retrospective | CR/PR | SD/PD | RR, DCR, PFS, OS, adverse events |
Lee 2014[1] | Korea, Taiwan | Asian | Mutant EGFR-NSCLC | 146 | 39.20% | IIIB-IV | Gefitinib, erlotinib, afatinib | RESCIST 1.1 | Prospective | CR/PR | SD/PD | RR, PFS, OS |
Zhao 2014 | China | Asian | Mutant EGFR-NSCLC | 166 | 48.20% | IIIB- IV | Gefitinib, erlotinib | RESCIST 1.1 | Retrospective | CR/PR | SD/PD | RR, DCR, PFS |
